Biotherapic of Toxoplasma gondii reduces parasite load, improves experimental infection, protects myenteric neurons and modulates the immune response in mice with toxoplasmosis

Introduction: The evaluation of an ultradiluted medication in toxoplasmosis, will contribute to the understanding of the mechanism of action of homeopathic medications. This study evaluated the effect of the dynamization 200dH of T. gondii biotherapic in mice. Methods: In a blind, controlled, randomized assay, 45 Swiss male mice, were divided: GCN: uninfected and untreated control group(n = 15); GCinf: infected control group pretreated with 7% grain alcohol(n = 15); BIOT- TG200: pretreated with 200dHT. gondii medicine(n = 15). Medicines were prepared according to the Brazilian Homeopathic Pharmacopoeia. Clinical, parasitological, histopathological, and immunological parameters were evaluated on the 30th and 60th day post-infection(dpi). Results: A favorable clinical outcome was observed for mice treated with BIOT- TG200 the study. The number of brain cysts was reduced in the BIOT- TG200 group on the 30th(p < 0.01) and 60th dpi(p < 0.05), compared with GCinf. There was myenteric neuronal protection in the colon of mice treated with BIOTTG200 and for proinflammatory cytokines there was an increase of IFN-g at 30 and 60 dpi and decrease over the course of infection. The cytokine IL-6 increased at 30 dpi and decreased over the course of infection. TNF-alpha increased at 30 dpi and reduced over the course of infection. For IL- 17 there was a reduction over the course of infection. There was no significant variation in IL-2. The anti-inflammatory cytokine IL- 10 decreased over the course of infection and IL- 4 did not vary significantly, predominantly in Th1 response. Conclusion: There was beneficial effect of the highly diluted biotherapic of T. gondii, promoting more favorable clinical symptomatology, parasite load reduction, neuronal protection and immune system modulation. (C) 2016 Elsevier GmbH. All rights reserved.